Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 1;42(28):2207–2217. doi: 10.1038/s41388-023-02737-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Schematic of signaling in the mTOR pathway. An example inhibitor of each class is indicated. RTKs, receptor tyrosine kinases; PI3K, Phosphatidylinositol-3-kinase. B Chemical structure of RMC-6272 C MCF-7 cells treated with everolimus, INK128 or RMC-6272 for 4 h at indicated doses. Cell lysates were assessed for mTORC1 activity by immunoblotting the phosphorylation of S6 (pS6) at S240/244, the phosphorylation of 4EBP1 (p4EBP1) at T37/46, and for mTORC2 activity by the phosphorylation of AKT (pAKT) at S473. Total S6, 4EBP1, AKT and β-Actin shown as controls. Image represents at least two independent experiments. D BT549 breast cancer cells were treated and analyzed as in (C). Image represents at least two independent experiments. E Quantification of blot intensities in (C) and (D) indicated phospho-proteins were quantified and normalized to actin and then again to total protein controls. Dotted line indicates 50% and 90% inhibition of signal from baseline.